Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Viktor Berge

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
The Prostate|April 3, 2018
Role of serum response factor expression in prostate cancer biochemical recurrenceMaria Prencipe, Aurelie Fabre, Thomas Brendan Murphy, et al.
European Urology Open Science|November 10, 2022
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate CancerIngrid Jenny Guldvik, Peder Rustøen Braadland, Shivanthe Sivanesan, et al.
BJU International|January 15, 2016
Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) studyLeonard P Bokhorst, Inari Lepistö, Yoshiyuki Kakehi, et al.
Carcinogenesis|February 20, 2021
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancerHåkon Ramberg, Elin Richardsen, Gustavo A de Souza, et al.
International Journal of Cancer|June 9, 2016
PBX3 is a putative biomarker of aggressive prostate cancerHåkon Ramberg, Helene Hartvedt Grytli, Ståle Nygård, et al.
Acta Oncologica (Stockholm, Sweden)|October 22, 2025
Development and evaluation of a lymph node invasion risk prediction model in intermediate- and high-risk prostate cancer patientsHåkon Ramberg, Manuela Zucknick, Francesco Barletta, et al.
Nature Reviews. Clinical Oncology|April 23, 2014
Can we deliver randomized trials of focal therapy in prostate cancer?Hashim U Ahmed, Viktor Berge, David Bottomley, et al.
Nature Reviews. Clinical Oncology|September 13, 2017
Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer?Hashim U Ahmed, Viktor Berge, David Bottomley, et al.
RSC Advances|May 11, 2022
Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat dietZhirui Fan, Lifeng Li, Xiaoli Li, et al.
Scientific Reports|July 13, 2017
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cellsXiaoran Li, Jie Lu, Quancheng Kan, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
The Prostate|April 3, 2018
Role of serum response factor expression in prostate cancer biochemical recurrenceMaria Prencipe, Aurelie Fabre, Thomas Brendan Murphy, et al.
European Urology Open Science|November 10, 2022
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate CancerIngrid Jenny Guldvik, Peder Rustøen Braadland, Shivanthe Sivanesan, et al.
BJU International|January 15, 2016
Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) studyLeonard P Bokhorst, Inari Lepistö, Yoshiyuki Kakehi, et al.
Carcinogenesis|February 20, 2021
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancerHåkon Ramberg, Elin Richardsen, Gustavo A de Souza, et al.
International Journal of Cancer|June 9, 2016
PBX3 is a putative biomarker of aggressive prostate cancerHåkon Ramberg, Helene Hartvedt Grytli, Ståle Nygård, et al.
Acta Oncologica (Stockholm, Sweden)|October 22, 2025
Development and evaluation of a lymph node invasion risk prediction model in intermediate- and high-risk prostate cancer patientsHåkon Ramberg, Manuela Zucknick, Francesco Barletta, et al.
Nature Reviews. Clinical Oncology|April 23, 2014
Can we deliver randomized trials of focal therapy in prostate cancer?Hashim U Ahmed, Viktor Berge, David Bottomley, et al.
Nature Reviews. Clinical Oncology|September 13, 2017
Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer?Hashim U Ahmed, Viktor Berge, David Bottomley, et al.
RSC Advances|May 11, 2022
Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat dietZhirui Fan, Lifeng Li, Xiaoli Li, et al.
Scientific Reports|July 13, 2017
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cellsXiaoran Li, Jie Lu, Quancheng Kan, et al.
Pageof 6